Industry News

Repros Therapeutics Inc. ® today announced that, as anticipated, it has activated the process for obtaining a marketing authorization for enclomiphene in the treatment of secondary hypogonadism in Europe. The MAA has been submitted today to the European Medicines Agency by Renable Pharma Limited, the U.K. subsidiary of Repros."/>
Repros Announces Submission of MAA to the European Medicines Agency for Enclomiphene in the Treatment of Secondary Hypogonadism
Ensign Group, Inc.' s home health and hospice portfolio subsidiary Meridian, Idaho-based hospices services company Cornerstone Healthcare, Inc. has acquired the assets of Abilene, Texas-based Kinder Hearts Home Health and Hospice, effective 1 September 2016, the company said. Terms of the deal were not disclosed. With the acquisition, Cornerstone subsidiaries now operate 17 home health operations, seventeen hospice..."/>
Ensign Acquires Texas-based Kinder Hearts Home Health and Hospice
HMS Holdings Corp. has acquired Longmont, Colorado-based care management platform provider Essette for USD 20 m, the company said. The approximately USD 20 m purchase was funded with available cash. This platform helps risk-bearing healthcare organisations identify, engage, and manage at-risk patient populations to improve outcomes while managing costs."/>
Texas Benefits Coordinator HMS Holdings Acquires Essette for USD 20m
Quorum Health Corporation securities on or before August 10, 2016. The deadline to move for appointment as lead plaintiff in the case is November 8, 2016.. The lawsuit, which is pending in the United States District Court for the Middle District of Tennessee, alleges, among other things, that Quorum overstated the performance of its hospitals and its goodwill."/>
INVESTOR ALERT: Class Action Lawsuit on Behalf of Investors in Quorum Health Filed by Holzer & Holzer
Prestige Brands Holdings, Inc., a leading marketer of over-the-counter healthcare products, today announced the appointment of Christine“ Chris” Sacco to the position of Chief Financial Officer for the Company. Sacco is a seasoned public company chief financial officer, bringing more than 19 years of experience in corporate finance, treasury, investor relations, strategic planning, operations and mergers and acquisitions focused on consumer products and..."/>
Prestige Brands Holdings, Inc. Appoints Christine Sacco as New Chief Financial Officer
Genmab A/S. COPENHAGEN, Denmark, Sept. 12, 2016-- Genmab A/S announces under reference to Section 29 of the Danish Securities Trading Act that FIL Investment Management Limited has informed us that, as of September 9, 2016, FMR LLC has decreased their indirect ownership in Genmab A/S to 2,975,738 shares, which amounts to 4.94% of the share capital and voting rights in Genmab A/S.. About Genmab Genmab is a publicly traded, international..."/>
Major Shareholder Announcement
Cigna’ s new automatic claims submission feature represents a customer-centric approach to voluntary benefits Customers with accidental injury or critical illness coverage will have their claim automatically initiated through Cigna’ s disability claim process Cigna's group insurance benefits are designed to complement a comprehensive benefit package and address the financial protection needs of customers. PHILADELPHIA---- Just in time for enrollment season, Cigna is..."/>
Cigna Short-Term Disability and Voluntary Benefits Claims Process Getting Easier for Consumers
BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, today announced that the Journal of Translational Medicine has published the results of a long-term safety and feasibility study of the injection of autologous, hypoxic cultured mesenchymal stem cells into patients with chronic lumbar degenerative disc disease related to protruding/bulging discs. The Company is preparing for an Investigational New..."/>
BioRestorative Therapies Announces Publication in Medical Journal of Positive Results of Long-Term Safety and Feasibility Study Using Cell Therapy to Treat Patients with Degenerative Disc Disease
Aethlon Medical, Inc., announced today that Jim Joyce, Chairman and CEO, and Jim Frakes, Chief Financial Officer, will be presenting at the Rodman& Renshaw 18 th Annual Global Investment Conference in New York, NY at 2:10 p.m. ET on Tuesday, September 13, 2016.. The presentation will be made available to the public via live audio webcast which can be accessed by visiting the investor relations section of Aethlon Medical's corporate website at..."/>
Aethlon Medical To Present At The Rodman & Renshaw 18th Annual Global Investment Conference On September 13, 2016
InMed Pharmaceuticals, Inc., a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today that it will present at the Rodman& Renshaw 18th Annual Global Investment/Healthcare Conference. The Conference will be held September 11-13, 2016 at the Lotte New York Palace Hotel, New York City. William Garner M.D., a Director of InMed Pharmaceuticals, will present a corporate..."/>
InMed to Present at 18th Annual Rodman and Renshaw Global Investment Conference
Asterias Biotherapeutics, Inc., a biotechnology company focused on the emerging field of regenerative medicine, announced that Steve Cartt, President and Chief Executive Officer, will present at the Rodman& Renshaw 18th Annual Global Investment Conference today, Monday, September 12, 2016 at 5:05 PM Eastern Time at The Lotte New York Palace Hotel. A live webcast of the presentation will be accessible at..."/>
Asterias Biotherapeutics to Present at Rodman & Renshaw Annual Global Investment Conference Today, September 12, 2016, in Advance of Upcoming Interim Efficacy Data Release from Spinal Cord Injury Trial
CytoDyn Inc., a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus infection, today announced that it has entered into definitive agreements with healthcare dedicated institutional investors for an offering of 13,333,334 shares of common stock, at a price per share of $0.75, and warrants to purchase 6,666,667 shares of common stock with gross proceeds of..."/>
CytoDyn Announces $10.0 Million Registered Direct Offering
Cerecor Inc., a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has entered into a $15 million common stock purchase agreement and a registration rights agreement with Aspire Capital Fund, LLC, a Chicago-based institutional investor. Under the terms of the Agreement, Aspire has made an initial purchase of $1 million of Cerecor..."/>
Cerecor Enters Into a $15 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
SQI Diagnostics Inc., today announced that it has sold its second sqid lite-DH system in its diagnostic business segment. Management believes that sale of the second system to a single customer marks an important milestone in the commercialization of its customer's multiplexed DNA test for infections in human blood in the US market. "We are growing our business with this important customer to SQI."/>
SQI Sells Second sqidlite™-DH System to Diagnostics Segment Customer
PRA Health Sciences, Inc. and Takeda Pharmaceutical Company Limited announced today that the companies have entered into a new partnership agreement under which PRA Health Sciences will serve as Takeda’ s primary strategic partner to deliver on the company’ s pipeline and marketed products clinical development and post-approval needs."/>
Takeda and PRA Health Sciences Announce Transformational Clinical Development and Marketed Product Partnership
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that results from its on-going Phase 1 b/2 trial of aldoxorubicin in combination with ifosfamide/mesna in patients with advanced sarcomas will be presented at the European Society for Medical Oncology 2016 Congress being held in Copenhagen, Denmark, from October 7-11, 2016.. "Presenting the results from this trial at the..."/>
CytRx to Present Data at the European Society for Medical Oncology 2016 Congress from Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial
Taxus Cardium Pharmaceuticals Group Inc., today announced that the U.S. FDA Center for Biologics Evaluation and Research has cleared the Angionetics' Generx ® angiogenic gene therapy cardiac biologic product candidate for Phase 3 clinical study as a new, single dose, treatment for patients with myocardial ischemia and refractory angina due to advanced coronary artery disease."/>
Angionetics' Generx® [Ad5FGF-4] Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease
SQI Diagnostics Inc., today announced that it has sold its second sqid lite-DH system in its diagnostic business segment. Management believes that sale of the second system to a single customer marks an important milestone in the commercialization of its customer's multiplexed DNA test for infections in human blood in the US market. "We are growing our business with this important customer to SQI."/>
SQI Sells Second sqidlite™-DH System to Diagnostics Segment Customer
Laboratory Corporation of America ® Holdings announced today that for the period of September 12, 2016 to March 10, 2017, its Zero Coupon Convertible Subordinated Notes due 2021 will, subject to the terms of the Zero Coupon Notes, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading days ended September 9, 2016, in addition to the continued accrual of the original issue discount."/>
LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest
Delcath Systems, Inc., an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that a research team led by Dr. Mark C. Burgmans at Leiden University Medical Center in the Netherlands has received the prestigious Outstanding Service Award from Cardiovascular& Interventional Radiology, a leading peer-reviewed medical journal. The LUMC team were recognized for their review of the Delcath..."/>
Researchers at leiden univeristy medical center receive outstanding service award for Publication on Delcath's Melphalan/HDS
ESSA Pharma Inc. a clinical stage company focused on the development of small molecule drugs for the treatment of cancer, today announced David R. Parkinson, President and Chief Executive Officer will be presenting at the Rodman& Renshaw 18 th Annual Global Investment Conference in New York City on Tuesday September 13 th at 11:15 AM Eastern Time at the Lotte New York Palace Hotel. Parkinson will provide a corporate..."/>
ESSA Pharma to present at Rodman & Renshaw 18th Annual Global Investment Conference
ESSA Pharma Inc. a clinical stage company focused on the development of small molecule drugs for the treatment of cancer, today announced David R. Parkinson, President and Chief Executive Officer will be presenting at the Rodman& Renshaw 18 th Annual Global Investment Conference in New York City on Tuesday September 13 th at 11:15 AM Eastern Time at the Lotte New York Palace Hotel. Parkinson will provide a corporate overview of..."/>
ESSA Pharma to present at Rodman & Renshaw 18th Annual Global Investment Conference

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology629 Articles
Consumer Discretionary552 Articles
Financials342 Articles
Industrials342 Articles
Health Care322 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.